Shares of LivaNova LIVN were unchanged at $56.37 after the company reported Q1 results.
Quarterly Results
Earnings per share decreased 38.89% over the past year to $0.33, which missed the estimate of $0.43.
Revenue of $242,400,000 lower by 3.35% year over year, which missed the estimate of $244,100,000.
Guidance
LivaNova hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Apr 29, 2020
Time: 08:05 AM ET
Webcast URL: https://edge.media-server.com/mmc/p/hrqp7xsh
Recent Stock Performance
52-week high: $87.45
Company's 52-week low was at $33.40
Price action over last quarter: down 18.17%
Company Profile
U.K.-based LivaNova was born of a combination between Cyberonics in the U.S. and Sorin in Italy. The medical device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. LivaNova derives roughly half of its revenue from the U.S. market, another 21% from Europe, and the remainder from the rest of the world.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
